JP2022115998A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022115998A5 JP2022115998A5 JP2022076787A JP2022076787A JP2022115998A5 JP 2022115998 A5 JP2022115998 A5 JP 2022115998A5 JP 2022076787 A JP2022076787 A JP 2022076787A JP 2022076787 A JP2022076787 A JP 2022076787A JP 2022115998 A5 JP2022115998 A5 JP 2022115998A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- factor
- protein
- inhibitors
- therapeutic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004169 proteins and genes Human genes 0.000 claims 9
- 108090000623 proteins and genes Proteins 0.000 claims 9
- 230000001225 therapeutic effect Effects 0.000 claims 8
- 239000002539 nanocarrier Substances 0.000 claims 7
- 239000002105 nanoparticle Substances 0.000 claims 6
- 102000004190 Enzymes Human genes 0.000 claims 5
- 108090000790 Enzymes Proteins 0.000 claims 5
- 230000002009 allergenic effect Effects 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- -1 buckyballs Substances 0.000 claims 5
- 229940088598 enzyme Drugs 0.000 claims 5
- 229920000728 polyester Polymers 0.000 claims 5
- 108090000695 Cytokines Proteins 0.000 claims 4
- 102000004127 Cytokines Human genes 0.000 claims 4
- 208000003455 anaphylaxis Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 3
- 239000003018 immunosuppressive agent Substances 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- 229920000570 polyether Polymers 0.000 claims 3
- 102100031491 Arylsulfatase B Human genes 0.000 claims 2
- 101001018026 Homo sapiens Lysosomal alpha-glucosidase Proteins 0.000 claims 2
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 claims 2
- 208000015439 Lysosomal storage disease Diseases 0.000 claims 2
- 108010027520 N-Acetylgalactosamine-4-Sulfatase Proteins 0.000 claims 2
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 claims 2
- 102000004179 Plasminogen Activator Inhibitor 2 Human genes 0.000 claims 2
- 108090000614 Plasminogen Activator Inhibitor 2 Proteins 0.000 claims 2
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 claims 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 102000045921 human GAA Human genes 0.000 claims 2
- 108010072166 idursulfase Proteins 0.000 claims 2
- 229940125721 immunosuppressive agent Drugs 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 229940124302 mTOR inhibitor Drugs 0.000 claims 2
- 229920002521 macromolecule Polymers 0.000 claims 2
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 2
- 239000002082 metal nanoparticle Substances 0.000 claims 2
- 108010025221 plasma protein Z Proteins 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 229960000187 tissue plasminogen activator Drugs 0.000 claims 2
- PNFORBBPPMQASU-JTQLQIEISA-N (2s)-2-amino-6-[[4-(2-methoxyethoxy)-4-oxobutanoyl]amino]hexanoic acid Chemical compound COCCOC(=O)CCC(=O)NCCCC[C@H](N)C(O)=O PNFORBBPPMQASU-JTQLQIEISA-N 0.000 claims 1
- 108090000935 Antithrombin III Proteins 0.000 claims 1
- 102000004411 Antithrombin III Human genes 0.000 claims 1
- 102000019034 Chemokines Human genes 0.000 claims 1
- 108010012236 Chemokines Proteins 0.000 claims 1
- 102100022641 Coagulation factor IX Human genes 0.000 claims 1
- 102100023804 Coagulation factor VII Human genes 0.000 claims 1
- 108010076282 Factor IX Proteins 0.000 claims 1
- 108010014172 Factor V Proteins 0.000 claims 1
- 108010023321 Factor VII Proteins 0.000 claims 1
- 108010054218 Factor VIII Proteins 0.000 claims 1
- 102000001690 Factor VIII Human genes 0.000 claims 1
- 108010014173 Factor X Proteins 0.000 claims 1
- 108010080865 Factor XII Proteins 0.000 claims 1
- 102000000429 Factor XII Human genes 0.000 claims 1
- 108010071289 Factor XIII Proteins 0.000 claims 1
- 108010074860 Factor Xa Proteins 0.000 claims 1
- 102100037362 Fibronectin Human genes 0.000 claims 1
- 108010067306 Fibronectins Proteins 0.000 claims 1
- 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 claims 1
- 206010053185 Glycogen storage disease type II Diseases 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 108090000481 Heparin Cofactor II Proteins 0.000 claims 1
- 102100030500 Heparin cofactor 2 Human genes 0.000 claims 1
- 108010000487 High-Molecular-Weight Kininogen Proteins 0.000 claims 1
- 102000004157 Hydrolases Human genes 0.000 claims 1
- 108090000604 Hydrolases Proteins 0.000 claims 1
- 102100029199 Iduronate 2-sulfatase Human genes 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 102000015696 Interleukins Human genes 0.000 claims 1
- 108010063738 Interleukins Proteins 0.000 claims 1
- 102000004195 Isomerases Human genes 0.000 claims 1
- 108090000769 Isomerases Proteins 0.000 claims 1
- 102100035792 Kininogen-1 Human genes 0.000 claims 1
- 102000003960 Ligases Human genes 0.000 claims 1
- 108090000364 Ligases Proteins 0.000 claims 1
- 108090000856 Lyases Proteins 0.000 claims 1
- 102000004317 Lyases Human genes 0.000 claims 1
- 102100033342 Lysosomal acid glucosylceramidase Human genes 0.000 claims 1
- 102000004316 Oxidoreductases Human genes 0.000 claims 1
- 108090000854 Oxidoreductases Proteins 0.000 claims 1
- 239000012826 P38 inhibitor Substances 0.000 claims 1
- 108090000113 Plasma Kallikrein Proteins 0.000 claims 1
- 102000013566 Plasminogen Human genes 0.000 claims 1
- 108010051456 Plasminogen Proteins 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 229920002873 Polyethylenimine Polymers 0.000 claims 1
- 229920000954 Polyglycolide Polymers 0.000 claims 1
- 239000004721 Polyphenylene oxide Substances 0.000 claims 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 1
- 229940079156 Proteasome inhibitor Drugs 0.000 claims 1
- 101800004937 Protein C Proteins 0.000 claims 1
- 102000017975 Protein C Human genes 0.000 claims 1
- 229940096437 Protein S Drugs 0.000 claims 1
- 108010066124 Protein S Proteins 0.000 claims 1
- 102000029301 Protein S Human genes 0.000 claims 1
- 108010094028 Prothrombin Proteins 0.000 claims 1
- 101800001700 Saposin-D Proteins 0.000 claims 1
- 108010000499 Thromboplastin Proteins 0.000 claims 1
- 102000002262 Thromboplastin Human genes 0.000 claims 1
- 102000004357 Transferases Human genes 0.000 claims 1
- 108090000992 Transferases Proteins 0.000 claims 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 229960001239 agalsidase alfa Drugs 0.000 claims 1
- 108010049936 agalsidase alfa Proteins 0.000 claims 1
- 229960004470 agalsidase beta Drugs 0.000 claims 1
- 108010056760 agalsidase beta Proteins 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 229940022705 aldurazyme Drugs 0.000 claims 1
- 229960004593 alglucosidase alfa Drugs 0.000 claims 1
- 239000013566 allergen Substances 0.000 claims 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 claims 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 claims 1
- 102000003801 alpha-2-Antiplasmin Human genes 0.000 claims 1
- 108090000183 alpha-2-Antiplasmin Proteins 0.000 claims 1
- 108010028144 alpha-Glucosidases Proteins 0.000 claims 1
- 229960005348 antithrombin iii Drugs 0.000 claims 1
- 229920006187 aquazol Polymers 0.000 claims 1
- 229960003270 belimumab Drugs 0.000 claims 1
- 239000003114 blood coagulation factor Substances 0.000 claims 1
- 108090001015 cancer procoagulant Proteins 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000000701 coagulant Substances 0.000 claims 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 239000000412 dendrimer Substances 0.000 claims 1
- 229920000736 dendritic polymer Polymers 0.000 claims 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims 1
- 229960002986 dinoprostone Drugs 0.000 claims 1
- 238000009826 distribution Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000002296 dynamic light scattering Methods 0.000 claims 1
- QBEPNUQJQWDYKU-BMGKTWPMSA-N egrifta Chemical compound C([C@H](NC(=O)C/C=C/CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(N)=O)C1=CC=C(O)C=C1 QBEPNUQJQWDYKU-BMGKTWPMSA-N 0.000 claims 1
- 229940012882 elaprase Drugs 0.000 claims 1
- KUBARPMUNHKBIQ-VTHUDJRQSA-N eliglustat tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C([C@@H](NC(=O)CCCCCCC)[C@H](O)C=1C=C2OCCOC2=CC=1)N1CCCC1.C([C@@H](NC(=O)CCCCCCC)[C@H](O)C=1C=C2OCCOC2=CC=1)N1CCCC1 KUBARPMUNHKBIQ-VTHUDJRQSA-N 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 238000002641 enzyme replacement therapy Methods 0.000 claims 1
- 229960004222 factor ix Drugs 0.000 claims 1
- 229940012413 factor vii Drugs 0.000 claims 1
- 229960000301 factor viii Drugs 0.000 claims 1
- 229940012426 factor x Drugs 0.000 claims 1
- 229940012444 factor xiii Drugs 0.000 claims 1
- 108010089296 galsulfase Proteins 0.000 claims 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 201000004502 glycogen storage disease II Diseases 0.000 claims 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims 1
- 239000010931 gold Substances 0.000 claims 1
- 229910052737 gold Inorganic materials 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 108010013846 hematide Proteins 0.000 claims 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 229960002396 idursulfase Drugs 0.000 claims 1
- 229960002127 imiglucerase Drugs 0.000 claims 1
- 108010039650 imiglucerase Proteins 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 229940047124 interferons Drugs 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 229960002486 laronidase Drugs 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 229940091827 lumizyme Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000004898 mitochondrial function Effects 0.000 claims 1
- 229940103023 myozyme Drugs 0.000 claims 1
- 229940068704 naglazyme Drugs 0.000 claims 1
- 239000002070 nanowire Substances 0.000 claims 1
- 229950005751 ocrelizumab Drugs 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 1
- 229920001983 poloxamer Polymers 0.000 claims 1
- 229920001308 poly(aminoacid) Polymers 0.000 claims 1
- 229920000747 poly(lactic acid) Polymers 0.000 claims 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 1
- 229920001610 polycaprolactone Polymers 0.000 claims 1
- 239000004632 polycaprolactone Substances 0.000 claims 1
- 229920000515 polycarbonate Polymers 0.000 claims 1
- 239000004417 polycarbonate Substances 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920001855 polyketal Polymers 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 229920006324 polyoxymethylene Polymers 0.000 claims 1
- 229920001451 polypropylene glycol Polymers 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 claims 1
- 239000003207 proteasome inhibitor Substances 0.000 claims 1
- 229960000856 protein c Drugs 0.000 claims 1
- 239000003379 purinergic P1 receptor agonist Substances 0.000 claims 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
- 238000009256 replacement therapy Methods 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000009469 supplementation Effects 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 229960001832 taliglucerase alfa Drugs 0.000 claims 1
- 108010072309 taliglucerase alfa Proteins 0.000 claims 1
- 229960001874 tesamorelin Drugs 0.000 claims 1
- 108700002800 tesamorelin Proteins 0.000 claims 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229960003989 tocilizumab Drugs 0.000 claims 1
- 229960005356 urokinase Drugs 0.000 claims 1
- 108010047303 von Willebrand Factor Proteins 0.000 claims 1
- 102100036537 von Willebrand factor Human genes 0.000 claims 1
- 229960001134 von willebrand factor Drugs 0.000 claims 1
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361819517P | 2013-05-03 | 2013-05-03 | |
| US61/819,517 | 2013-05-03 | ||
| US201361881913P | 2013-09-24 | 2013-09-24 | |
| US201361881851P | 2013-09-24 | 2013-09-24 | |
| US201361881921P | 2013-09-24 | 2013-09-24 | |
| US61/881,913 | 2013-09-24 | ||
| US61/881,851 | 2013-09-24 | ||
| US61/881,921 | 2013-09-24 | ||
| US201361907177P | 2013-11-21 | 2013-11-21 | |
| US61/907,177 | 2013-11-21 | ||
| US201461948313P | 2014-03-05 | 2014-03-05 | |
| US201461948384P | 2014-03-05 | 2014-03-05 | |
| US61/948,384 | 2014-03-05 | ||
| US61/948,313 | 2014-03-05 | ||
| JP2019004287A JP7134885B2 (ja) | 2013-05-03 | 2019-01-15 | 非アレルゲン性の抗原に応答するアナフィラキシーを低減または防止するための寛容原性合成ナノ担体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019004287A Division JP7134885B2 (ja) | 2013-05-03 | 2019-01-15 | 非アレルゲン性の抗原に応答するアナフィラキシーを低減または防止するための寛容原性合成ナノ担体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022115998A JP2022115998A (ja) | 2022-08-09 |
| JP2022115998A5 true JP2022115998A5 (https=) | 2023-01-31 |
| JP7440833B2 JP7440833B2 (ja) | 2024-02-29 |
Family
ID=51841530
Family Applications (19)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016512092A Active JP6760838B2 (ja) | 2013-05-03 | 2014-05-02 | 望ましくない液性免疫応答を低減するための投薬の組み合わせ |
| JP2016512094A Active JP6580558B2 (ja) | 2013-05-03 | 2014-05-02 | Ｃｄ４＋制御性ｔ細胞を増強するための方法および組成物 |
| JP2016512093A Active JP6818549B2 (ja) | 2013-05-03 | 2014-05-02 | 非アレルゲン性の抗原に応答するアナフィラキシーを低減または防止するための寛容原性合成ナノ担体 |
| JP2016512086A Pending JP2016517889A (ja) | 2013-05-03 | 2014-05-02 | 薬力学的効果の低減または向上のための寛容原性合成ナノ担体および治療用高分子 |
| JP2016512091A Active JP7028556B2 (ja) | 2013-05-03 | 2014-05-02 | 特定の薬力学的有効期間および免疫寛容の誘発のための抗原を有する免疫抑制剤の送達 |
| JP2016512090A Pending JP2016520051A (ja) | 2013-05-03 | 2014-05-02 | Ｉ型およびｉｖ型過敏症を低減させる寛容原性の合成ナノ担体の局所的な併用投与 |
| JP2018231206A Active JP6983144B2 (ja) | 2013-05-03 | 2018-12-10 | 薬力学的効果の低減または向上のための寛容原性合成ナノ担体および治療用高分子 |
| JP2019004287A Active JP7134885B2 (ja) | 2013-05-03 | 2019-01-15 | 非アレルゲン性の抗原に応答するアナフィラキシーを低減または防止するための寛容原性合成ナノ担体 |
| JP2019155456A Pending JP2020015741A (ja) | 2013-05-03 | 2019-08-28 | Ｃｄ４＋制御性ｔ細胞を増強するための方法および組成物 |
| JP2019195263A Active JP7427419B2 (ja) | 2013-05-03 | 2019-10-28 | 望ましくない液性免疫応答を低減するための投薬の組み合わせ |
| JP2019217946A Pending JP2020073488A (ja) | 2013-05-03 | 2019-12-02 | 特定の薬力学的有効期間および免疫寛容の誘発のための抗原を有する免疫抑制剤の送達 |
| JP2021000191A Pending JP2021073198A (ja) | 2013-05-03 | 2021-01-04 | 薬力学的効果の低減または向上のための寛容原性合成ナノ担体および治療用高分子 |
| JP2021162235A Active JP7489362B2 (ja) | 2013-05-03 | 2021-09-30 | 薬力学的効果の低減または向上のための寛容原性合成ナノ担体および治療用高分子 |
| JP2021193530A Pending JP2022043071A (ja) | 2013-05-03 | 2021-11-29 | 望ましくない液性免疫応答を低減するための投薬の組み合わせ |
| JP2022076702A Pending JP2022122871A (ja) | 2013-05-03 | 2022-05-06 | 特定の薬力学的有効期間および免疫寛容の誘発のための抗原を有する免疫抑制剤の送達 |
| JP2022076787A Active JP7440833B2 (ja) | 2013-05-03 | 2022-05-06 | 非アレルゲン性の抗原に応答するアナフィラキシーを低減または防止するための寛容原性合成ナノ担体 |
| JP2022197386A Pending JP2023039981A (ja) | 2013-05-03 | 2022-12-09 | Ｃｄ４＋制御性ｔ細胞を増強するための方法および組成物 |
| JP2024077998A Pending JP2024116128A (ja) | 2013-05-03 | 2024-05-13 | 薬力学的効果の低減または向上のための寛容原性合成ナノ担体および治療用高分子 |
| JP2024159048A Withdrawn JP2025003994A (ja) | 2013-05-03 | 2024-09-13 | 特定の薬力学的有効期間および免疫寛容の誘発のための抗原を有する免疫抑制剤の送達 |
Family Applications Before (15)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016512092A Active JP6760838B2 (ja) | 2013-05-03 | 2014-05-02 | 望ましくない液性免疫応答を低減するための投薬の組み合わせ |
| JP2016512094A Active JP6580558B2 (ja) | 2013-05-03 | 2014-05-02 | Ｃｄ４＋制御性ｔ細胞を増強するための方法および組成物 |
| JP2016512093A Active JP6818549B2 (ja) | 2013-05-03 | 2014-05-02 | 非アレルゲン性の抗原に応答するアナフィラキシーを低減または防止するための寛容原性合成ナノ担体 |
| JP2016512086A Pending JP2016517889A (ja) | 2013-05-03 | 2014-05-02 | 薬力学的効果の低減または向上のための寛容原性合成ナノ担体および治療用高分子 |
| JP2016512091A Active JP7028556B2 (ja) | 2013-05-03 | 2014-05-02 | 特定の薬力学的有効期間および免疫寛容の誘発のための抗原を有する免疫抑制剤の送達 |
| JP2016512090A Pending JP2016520051A (ja) | 2013-05-03 | 2014-05-02 | Ｉ型およびｉｖ型過敏症を低減させる寛容原性の合成ナノ担体の局所的な併用投与 |
| JP2018231206A Active JP6983144B2 (ja) | 2013-05-03 | 2018-12-10 | 薬力学的効果の低減または向上のための寛容原性合成ナノ担体および治療用高分子 |
| JP2019004287A Active JP7134885B2 (ja) | 2013-05-03 | 2019-01-15 | 非アレルゲン性の抗原に応答するアナフィラキシーを低減または防止するための寛容原性合成ナノ担体 |
| JP2019155456A Pending JP2020015741A (ja) | 2013-05-03 | 2019-08-28 | Ｃｄ４＋制御性ｔ細胞を増強するための方法および組成物 |
| JP2019195263A Active JP7427419B2 (ja) | 2013-05-03 | 2019-10-28 | 望ましくない液性免疫応答を低減するための投薬の組み合わせ |
| JP2019217946A Pending JP2020073488A (ja) | 2013-05-03 | 2019-12-02 | 特定の薬力学的有効期間および免疫寛容の誘発のための抗原を有する免疫抑制剤の送達 |
| JP2021000191A Pending JP2021073198A (ja) | 2013-05-03 | 2021-01-04 | 薬力学的効果の低減または向上のための寛容原性合成ナノ担体および治療用高分子 |
| JP2021162235A Active JP7489362B2 (ja) | 2013-05-03 | 2021-09-30 | 薬力学的効果の低減または向上のための寛容原性合成ナノ担体および治療用高分子 |
| JP2021193530A Pending JP2022043071A (ja) | 2013-05-03 | 2021-11-29 | 望ましくない液性免疫応答を低減するための投薬の組み合わせ |
| JP2022076702A Pending JP2022122871A (ja) | 2013-05-03 | 2022-05-06 | 特定の薬力学的有効期間および免疫寛容の誘発のための抗原を有する免疫抑制剤の送達 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022197386A Pending JP2023039981A (ja) | 2013-05-03 | 2022-12-09 | Ｃｄ４＋制御性ｔ細胞を増強するための方法および組成物 |
| JP2024077998A Pending JP2024116128A (ja) | 2013-05-03 | 2024-05-13 | 薬力学的効果の低減または向上のための寛容原性合成ナノ担体および治療用高分子 |
| JP2024159048A Withdrawn JP2025003994A (ja) | 2013-05-03 | 2024-09-13 | 特定の薬力学的有効期間および免疫寛容の誘発のための抗原を有する免疫抑制剤の送達 |
Country Status (15)
| Country | Link |
|---|---|
| US (15) | US10434088B2 (https=) |
| EP (7) | EP2991628A4 (https=) |
| JP (19) | JP6760838B2 (https=) |
| KR (18) | KR20240119155A (https=) |
| CN (18) | CN105338968A (https=) |
| AU (16) | AU2014262165B2 (https=) |
| BR (6) | BR122020023215B1 (https=) |
| CA (5) | CA2910417C (https=) |
| DK (1) | DK2991646T3 (https=) |
| EA (6) | EA201592107A1 (https=) |
| ES (1) | ES2842206T3 (https=) |
| HU (1) | HUE052599T2 (https=) |
| IL (14) | IL284732B2 (https=) |
| MX (12) | MX386917B (https=) |
| WO (5) | WO2014179762A1 (https=) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI1012036A2 (pt) | 2009-05-27 | 2017-10-10 | Selecta Biosciences Inc | nanocarreadores que possuem componentes com diferentes taxas de liberação |
| CA2798739A1 (en) | 2010-05-26 | 2011-12-01 | Selecta Biosciences, Inc. | Nanocarrier compositions with uncoupled adjuvant |
| EA201390660A1 (ru) | 2010-11-05 | 2013-11-29 | Селекта Байосайенсиз, Инк. | Модифицированные никотиновые соединения и связанные способы |
| MX374963B (es) | 2011-04-29 | 2025-03-06 | Selecta Biosciences Inc | Nanoportadores sintéticos tolerogénicos para reducir las respuestas de anticuerpos. |
| KR20140050698A (ko) | 2011-07-29 | 2014-04-29 | 셀렉타 바이오사이언시즈, 인크. | 체액성 및 세포독성 t 림프구(ctl) 면역 반응을 발생시키는 합성 나노운반체 |
| BR122020023215B1 (pt) | 2013-05-03 | 2022-11-22 | Selecta Biosciences, Inc | Composição e kit de nanocarreadores sintéticos tolerogênicos para reduzir ou prevenir anafilaxia em resposta a um antígeno não alergênico |
| JP7242180B2 (ja) | 2014-09-07 | 2023-03-20 | セレクタ バイオサイエンシーズ インコーポレーテッド | 抗ウイルス導入ベクター免疫応答を減弱化するための方法および組成物 |
| WO2017025889A1 (en) * | 2015-08-13 | 2017-02-16 | Pfizer Inc. | Polymeric nanoparticles with dec-205 ligand and co-encapsulating an antigen subject to an autoimmune response and a glucocorticoid receptor agonist |
| US10744209B2 (en) | 2015-11-12 | 2020-08-18 | New York University | Biodegradable polymeric nanoparticle conjugates and use thereof |
| KR20180120753A (ko) * | 2016-03-11 | 2018-11-06 | 셀렉타 바이오사이언시즈, 인크. | Peg화 우리카제의 제제 및 용량 |
| US11458106B2 (en) | 2016-05-09 | 2022-10-04 | Astrazeneca Ab | Lipid nanoparticles comprising lipophilic anti-inflammatory agents and methods of use thereof |
| US11365392B2 (en) * | 2016-08-05 | 2022-06-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Ex vivo generation of MHCII restricted CD4+ FOXP3+ regulatory T cells and therapeutic uses thereof |
| JP2019530470A (ja) * | 2016-08-05 | 2019-10-24 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | γδＦｏｘｐ３＋調節性Ｔ細胞のエクスビボ生成及びその治療的使用 |
| MX2019008143A (es) * | 2017-01-07 | 2020-01-13 | Selecta Biosciences Inc | Dosificación sistemática de inmunosupresores acoplados a nanoportadores sintéticos. |
| ES3036482T3 (en) * | 2017-03-11 | 2025-09-19 | Cartesian Therapeutics Inc | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
| BR112020007157A2 (pt) * | 2017-10-13 | 2020-09-24 | Selecta Biosciences, Inc. | métodos e composições para a atenuação de respostas de igm antivetor de transferência viral |
| WO2019129824A1 (en) * | 2017-12-27 | 2019-07-04 | Vito Nv | Biomarkers for typing allograft recipients |
| CN108295303A (zh) * | 2018-02-08 | 2018-07-20 | 中山大学附属第三医院（中山大学肝脏病医院） | 一种钛金属植入物及其制备方法和用途 |
| CN110314236A (zh) * | 2018-03-29 | 2019-10-11 | 天津键凯科技有限公司 | 聚乙二醇与雷帕霉素的结合物及其用途 |
| CN109045304B (zh) * | 2018-04-13 | 2022-04-05 | 中山大学 | 一种携带Polymerase I抑制剂的核仁靶向纳米载体及其制备方法和应用 |
| AU2020287627A1 (en) | 2019-06-04 | 2021-11-18 | Selecta Biosciences, Inc. | Formulations and doses of PEGylated uricase |
| WO2021016293A1 (en) * | 2019-07-22 | 2021-01-28 | University Of Louisville Research Foundation, Inc. | Immunomodulatory compositions and methods of using |
| EP4058006A4 (en) * | 2019-11-11 | 2023-06-28 | The Regents Of The University Of California | Polymeric nanoparticles that target liver sinusoidal endothelial cells to induce antigen-specific immune tolerance |
| CN110747276B (zh) * | 2019-11-22 | 2020-06-30 | 山东大学齐鲁医院 | Bace2作为胶质瘤预后/诊断/治疗标志物的应用 |
| AU2021225955A1 (en) * | 2020-02-26 | 2022-09-22 | Selecta Biosciences, Inc. | Methods and compositions using synthetic nanocarriers comprising immunosuppressant |
| IL297274A (en) * | 2020-04-14 | 2022-12-01 | Selecta Biosciences Inc | Methods and compositions for inducing autophagy |
| CN113825832B (zh) * | 2020-07-28 | 2024-12-13 | 浙江大学 | 一种体外诱导CD4+Foxp3+CD69+Treg的扩增方法及其用途 |
| WO2022022599A1 (zh) * | 2020-07-28 | 2022-02-03 | 浙江大学 | 一种体外诱导CD4 +Foxp3 +CD69 +Treg的扩增方法及其用途 |
| JP7544541B2 (ja) | 2020-09-14 | 2024-09-03 | 聡 安斎 | 地盤掘削装置 |
| CN112480244A (zh) * | 2020-11-24 | 2021-03-12 | 华科同济干细胞基因工程有限公司 | 一种抗过敏性纳米抗体组合物、抗体测定方法及喷雾剂 |
| CN112961831B (zh) * | 2021-02-26 | 2022-10-11 | 仲恺农业工程学院 | 一种肠源外泌体的制备方法 |
| WO2022221529A1 (en) | 2021-04-16 | 2022-10-20 | Asklepios Biopharmaceutical, Inc. | Rational polyploid aav virions that cross the blood brain barrier and elicit reduced humoral response |
| BR112023021962A2 (pt) * | 2021-04-22 | 2023-12-26 | Perseo Pharma Ag | Composições biocatalíticas funcionalizadas |
| JP2024545594A (ja) * | 2021-11-14 | 2024-12-10 | カーティザン セラピューティクス，インコーポレーテッド | ウイルスベクターでの複数回投薬 |
| WO2024129862A2 (en) * | 2022-12-13 | 2024-06-20 | Dana-Farber Cancer Institute, Inc. | Checkpoint modulators for enhancing immunotherapy |
| JPWO2024181580A1 (https=) | 2023-03-02 | 2024-09-06 | ||
| JPWO2024190532A1 (https=) | 2023-03-14 | 2024-09-19 | ||
| WO2025256978A1 (en) | 2024-06-13 | 2025-12-18 | Bayer Aktiengesellschaft | Variants of igm and igg cleaving enzymes |
| WO2025256977A1 (en) | 2024-06-13 | 2025-12-18 | Bayer Aktiengesellschaft | Novel igm and igg cleaving enzymes |
| GB202415232D0 (en) * | 2024-10-16 | 2024-11-27 | Nacamed As | Composition |
| CN121014614B (zh) * | 2025-11-03 | 2026-02-24 | 昆明医科大学 | 一种淋巴细胞保存液、制备方法及在样本预处理中的应用 |
Family Cites Families (294)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1995A (en) | 1841-03-03 | Latch of door and other locks | ||
| US4946929A (en) | 1983-03-22 | 1990-08-07 | Massachusetts Institute Of Technology | Bioerodible articles useful as implants and prostheses having predictable degradation rates |
| US4638045A (en) | 1985-02-19 | 1987-01-20 | Massachusetts Institute Of Technology | Non-peptide polyamino acid bioerodible polymers |
| US4806621A (en) | 1986-01-21 | 1989-02-21 | Massachusetts Institute Of Technology | Biocompatible, bioerodible, hydrophobic, implantable polyimino carbonate article |
| US5804178A (en) | 1986-11-20 | 1998-09-08 | Massachusetts Institute Of Technology | Implantation of cell-matrix structure adjacent mesentery, omentum or peritoneum tissue |
| CA1340581C (en) | 1986-11-20 | 1999-06-08 | Joseph P. Vacanti | Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices |
| US5736372A (en) | 1986-11-20 | 1998-04-07 | Massachusetts Institute Of Technology | Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure |
| EP0303681B1 (en) | 1987-02-24 | 1992-10-14 | Xoma Corporation | Immunosuppression in immunotoxin based human therapy |
| US5912017A (en) | 1987-05-01 | 1999-06-15 | Massachusetts Institute Of Technology | Multiwall polymeric microspheres |
| US5019379A (en) | 1987-07-31 | 1991-05-28 | Massachusetts Institute Of Technology | Unsaturated polyanhydrides |
| JP2670680B2 (ja) | 1988-02-24 | 1997-10-29 | 株式会社ビーエムジー | 生理活性物質含有ポリ乳酸系微小球およびその製造法 |
| US5010167A (en) | 1989-03-31 | 1991-04-23 | Massachusetts Institute Of Technology | Poly(amide-and imide-co-anhydride) for biological application |
| US5268455A (en) | 1989-05-25 | 1993-12-07 | Genentech, Inc. | Process for making biologically active polypeptides based on transforming growth factor-βsequences |
| US5399665A (en) | 1992-11-05 | 1995-03-21 | Massachusetts Institute Of Technology | Biodegradable polymers for cell transplantation |
| US5843452A (en) | 1992-11-09 | 1998-12-01 | Pharmagenesis, Inc. | Immunotherapy composition and method |
| US5679347A (en) | 1992-12-10 | 1997-10-21 | Brigham And Women's Hospital | Methods of isolating CD1-presented antigens, vaccines comprising CD1-presented antigens, and cell lines for use in said methods |
| DK0678034T3 (da) | 1993-01-11 | 1999-11-08 | Dana Farber Cancer Inst Inc | Induktion af cytotoksiske T-lymfocytreaktioner |
| US5512600A (en) | 1993-01-15 | 1996-04-30 | Massachusetts Institute Of Technology | Preparation of bonded fiber structures for cell implantation |
| US5514378A (en) | 1993-02-01 | 1996-05-07 | Massachusetts Institute Of Technology | Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures |
| WO1995003035A1 (en) | 1993-07-23 | 1995-02-02 | Massachusetts Institute Of Technology | Polymerized liposomes with enhanced stability for oral delivery |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| US5565215A (en) | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
| US5468729A (en) | 1993-10-26 | 1995-11-21 | Alpha 1 Biomedicals | Method for treatment of autoimmune hepatitis |
| ATE196297T1 (de) | 1994-05-18 | 2000-09-15 | Synthetic Peptides Inc | Heterodimere trägerzusammensetzung von immunogenen polypeptiden und verfahren zu deren verwendung |
| US6007845A (en) | 1994-07-22 | 1999-12-28 | Massachusetts Institute Of Technology | Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers |
| US5814617A (en) * | 1994-10-07 | 1998-09-29 | The United States Of America As Represented By The Secretary Of The Navy | Protective 17 KDA malaria hepatic and erythrocytic stage immunogen and gene |
| WO1996012406A1 (en) | 1994-10-19 | 1996-05-02 | Genetic Therapy, Inc. | Gene therapy involving concurrent and repeated administration of adenoviruses and immunosuppressive agents |
| US5716404A (en) | 1994-12-16 | 1998-02-10 | Massachusetts Institute Of Technology | Breast tissue engineering |
| ATE252894T1 (de) | 1995-01-05 | 2003-11-15 | Univ Michigan | Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung |
| US6251957B1 (en) | 1995-02-24 | 2001-06-26 | Trustees Of The University Of Pennsylvania | Method of reducing an immune response to a recombinant virus |
| US6123727A (en) | 1995-05-01 | 2000-09-26 | Massachusetts Institute Of Technology | Tissue engineered tendons and ligaments |
| JP3462313B2 (ja) | 1995-08-24 | 2003-11-05 | キッコーマン株式会社 | 変異型ウリカーゼ、変異型ウリカーゼ遺伝子、新規な組み換え体ｄｎａ及び変異型ウリカーゼの製造法 |
| US6095148A (en) | 1995-11-03 | 2000-08-01 | Children's Medical Center Corporation | Neuronal stimulation using electrically conducting polymers |
| DE19545257A1 (de) | 1995-11-24 | 1997-06-19 | Schering Ag | Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln |
| US5902599A (en) | 1996-02-20 | 1999-05-11 | Massachusetts Institute Of Technology | Biodegradable polymer networks for use in orthopedic and dental applications |
| AU735648B2 (en) | 1996-07-12 | 2001-07-12 | Ariad Pharmaceuticals, Inc. | Materials and method for treating or preventing pathogenic fungal infection |
| EP0889954A1 (en) | 1996-09-03 | 1999-01-13 | Health Research, Inc. | Treatment of antigen presenting cells to modulate antigen presenting cell function |
| US6060082A (en) | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
| US5837752A (en) | 1997-07-17 | 1998-11-17 | Massachusetts Institute Of Technology | Semi-interpenetrating polymer networks |
| CA2302779C (en) | 1997-09-16 | 2010-02-02 | Oregon Health Sciences University | Recombinant mhc molecules useful for manipulation of antigen-specific t-cells |
| CZ302352B6 (cs) | 1997-10-30 | 2011-03-30 | C. B. F. Leti, S. A. | Zpusob prípravy extraktu poskytujících toleranci proti alergenu a jejich použití |
| US6018817A (en) | 1997-12-03 | 2000-01-25 | International Business Machines Corporation | Error correcting code retrofit method and apparatus for multiple memory configurations |
| US6197229B1 (en) | 1997-12-12 | 2001-03-06 | Massachusetts Institute Of Technology | Method for high supercoiled DNA content microspheres |
| NZ505325A (en) | 1997-12-23 | 2003-07-25 | Crucell Holland B | Adeno-associated virus and adenovirus chimeric recombinant viruses useful for the integration of foreign genetic information into the chromosomal dna of target cells |
| GB2348808B (en) | 1998-01-09 | 2003-03-19 | Circassia Ltd | Methods and compositions for desensitisation |
| FR2775435B1 (fr) | 1998-02-27 | 2000-05-26 | Bioalliance Pharma | Nanoparticules comprenant au moins un polymere et au moins un compose apte a complexer un ou plusieurs principes actifs |
| US6686446B2 (en) | 1998-03-19 | 2004-02-03 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
| US6506577B1 (en) | 1998-03-19 | 2003-01-14 | The Regents Of The University Of California | Synthesis and crosslinking of catechol containing copolypeptides |
| US6632922B1 (en) | 1998-03-19 | 2003-10-14 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
| SE9801288D0 (sv) | 1998-04-14 | 1998-04-14 | Astra Ab | Vaccine delivery system and metod of production |
| US6436392B1 (en) | 1998-05-20 | 2002-08-20 | University Of Iowa Research Foundation | Adeno-associated virus vectors |
| RU2246318C2 (ru) | 1998-08-06 | 2005-02-20 | Маунтэн Вью Фармасьютикэлз, Инк. | Конъюгаты peg-уриказы и их использование |
| SK4272001A3 (en) | 1998-10-05 | 2003-02-04 | Pharmexa As | Methods for therapeutic vaccination |
| US6306640B1 (en) | 1998-10-05 | 2001-10-23 | Genzyme Corporation | Melanoma antigenic peptides |
| MEP42108A (en) | 1998-10-23 | 2011-02-10 | Kiren Amgen Inc | Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity |
| US6759237B1 (en) | 1998-11-05 | 2004-07-06 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same |
| ATE481487T1 (de) | 1998-11-27 | 2010-10-15 | Ucb Sa | Zusammensetzungen und verfahren zur erhöhung der knochenmineralisierung |
| US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
| US6153217A (en) * | 1999-01-22 | 2000-11-28 | Biodelivery Sciences, Inc. | Nanocochleate formulations, process of preparation and method of delivery of pharmaceutical agents |
| US6800296B1 (en) | 1999-05-19 | 2004-10-05 | Massachusetts Institute Of Technology | Modification of surfaces using biological recognition events |
| WO2000074688A1 (en) | 1999-06-08 | 2000-12-14 | The Children's Hospital Of Philadelphia | Methods for preventing formation of inhibitory antibodies in the setting of gene therapy |
| DE19951970A1 (de) | 1999-10-28 | 2001-05-03 | Bionetworks Gmbh | Arzneimittel für die Toleranzinduktion |
| JP4751556B2 (ja) | 2000-02-28 | 2011-08-17 | ジーンシーグス， インコーポレイテッド | ナノカプセルカプセル化システムおよび方法 |
| US20010055593A1 (en) | 2000-03-14 | 2001-12-27 | Joseph Sypek | Use of rapamycin and agents that inhibit B7 activity in immunomodulation |
| CA2407897A1 (en) | 2000-05-05 | 2001-11-15 | Cytos Biotechnology Ag | Molecular antigen arrays and vaccines |
| US20060057553A1 (en) | 2000-05-30 | 2006-03-16 | Estuardo Aguilar-Cordova | Chimeric viral vectors for gene therapy |
| ATE318923T1 (de) | 2000-06-01 | 2006-03-15 | Univ North Carolina | Doppelsträngige parvovirus-vektoren |
| AU2001269923A1 (en) | 2000-06-19 | 2002-01-02 | Genzyme Corporation | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| US20040204379A1 (en) | 2000-06-19 | 2004-10-14 | Cheng Seng H. | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| US20020014242A1 (en) | 2000-07-31 | 2002-02-07 | Abraham Scaria | Use of rapamycin to inhibit immune response and induce tolerance to gene therapy vector and encoded transgene products |
| MY138883A (en) * | 2000-08-29 | 2009-08-28 | Government Of Malaysia As Represented By The Ministry Of Science Tehnology And Innovation Malaysia | Use of asiatic acid for treatment of cencer |
| CA2319928A1 (en) | 2000-09-18 | 2002-03-18 | Vasogen Ireland Limited | Apoptosis-mimicking synthetic entities and use thereof in medical treatments |
| GB0025414D0 (en) | 2000-10-16 | 2000-11-29 | Consejo Superior Investigacion | Nanoparticles |
| WO2002088304A2 (en) | 2001-04-11 | 2002-11-07 | Trustees Of The University Of Pennsylvania | Compositions and methods for suppressing immune responses |
| US6913915B2 (en) | 2001-08-02 | 2005-07-05 | Phoenix Pharmacologics, Inc. | PEG-modified uricase |
| WO2003020797A1 (en) | 2001-08-30 | 2003-03-13 | The Regents Of The University Of California | Transition metal initiators for controlled poly (beta-peptide) synthesis from beta-lactam monomers |
| CN1294268C (zh) | 2001-09-03 | 2007-01-10 | 上海三维生物技术有限公司 | 可在肿瘤细胞内特异性复制并扩散的重组腺病毒载体 |
| MXPA04003625A (es) | 2001-10-19 | 2004-12-02 | Sotechnika Inc | Sintesis de analogos de ciclosporina. |
| PT1453547T (pt) | 2001-12-17 | 2016-12-28 | Univ Pennsylvania | Sequências do vírus adeno-associado (aav) do serotipo 8, vetores contendo as mesmas, e utilizações destas |
| GB0207440D0 (en) | 2002-03-28 | 2002-05-08 | Ppl Therapeutics Scotland Ltd | Tolerogenic antigen-presenting cells |
| US20040038303A1 (en) | 2002-04-08 | 2004-02-26 | Unger Gretchen M. | Biologic modulations with nanoparticles |
| US7485314B2 (en) | 2002-05-06 | 2009-02-03 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Induction of antigen specific immunologic tolerance |
| CA2486621A1 (en) | 2002-05-22 | 2003-12-04 | The Cleveland Clinic Foundation | Induction and maintenance of tolerance to composite tissue allografts |
| AU2003237416A1 (en) | 2002-06-04 | 2003-12-19 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Novel tolerogenic dendritic cells and therapeutic uses therefor |
| WO2004005476A2 (en) | 2002-07-03 | 2004-01-15 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US9809654B2 (en) | 2002-09-27 | 2017-11-07 | Vaccinex, Inc. | Targeted CD1d molecules |
| WO2004050090A1 (en) | 2002-11-29 | 2004-06-17 | Maria Grazia Roncarolo | Rapamycin and il-10 for the treatment of immune diseases |
| DE602004008582T2 (de) | 2003-02-17 | 2008-05-21 | Peter Burkhard | Peptidische nanoteilchen als arzneimittelabgabe- und antigen-display-systeme |
| US7510872B2 (en) | 2003-02-26 | 2009-03-31 | Nationwide Children's Hospital | Recombinant adeno-associated virus production |
| NZ542306A (en) | 2003-03-14 | 2008-04-30 | Wyeth Corp | Antibodies against human IL-21 receptor and uses therefor |
| AU2004224761A1 (en) | 2003-03-26 | 2004-10-07 | Cytos Biotechnology Ag | HIV-peptide-carrier-conjugates |
| US7186699B2 (en) | 2003-06-03 | 2007-03-06 | Cell Genesys, Inc. | Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes |
| US7727969B2 (en) | 2003-06-06 | 2010-06-01 | Massachusetts Institute Of Technology | Controlled release nanoparticle having bound oligonucleotide for targeted delivery |
| EP1486567A1 (en) | 2003-06-11 | 2004-12-15 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Improved adeno-associated virus (AAV) vector for gene therapy |
| CA2529623A1 (en) | 2003-06-16 | 2005-02-17 | Celltech R & D, Inc. | Antibodies specific for sclerostin and methods for increasing bone mineralization |
| US20060251711A1 (en) | 2003-08-28 | 2006-11-09 | Vgsk Technologies, Inc. | Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating diseases of the respiratory tract of a mammal |
| US20080160089A1 (en) | 2003-10-14 | 2008-07-03 | Medivas, Llc | Vaccine delivery compositions and methods of use |
| DE10347710B4 (de) | 2003-10-14 | 2006-03-30 | Johannes-Gutenberg-Universität Mainz | Rekombinante Impfstoffe und deren Verwendung |
| US20050175583A1 (en) | 2003-12-02 | 2005-08-11 | Lawrence Tamarkin | Methods and compositions for the production of monoclonal antibodies |
| MXPA06006738A (es) | 2003-12-19 | 2006-08-31 | Univ North Carolina | Metodos para fabricar micro- y nano-estructuras aisladas utilizando litografia suave o de impresion. |
| JP5080241B2 (ja) | 2004-04-08 | 2012-11-21 | メルク セローノ ソシエテ アノニム | Ｊｎｋ阻害剤およびスクロスポリンを含んでなる組成物 |
| CA2566506A1 (en) | 2004-06-01 | 2005-12-15 | Innogenetics N.V. | Peptides for inducing a ctl and/or htl response to hepatitis c virus |
| WO2006080951A2 (en) * | 2004-07-01 | 2006-08-03 | Yale University | Targeted and high density drug loaded polymeric materials |
| US20080206270A1 (en) | 2004-07-08 | 2008-08-28 | Minev Boris R | Enhancing Class I Antigen Presentation With Synthetic Sequences |
| FR2874384B1 (fr) | 2004-08-17 | 2010-07-30 | Genethon | Vecteur viral adeno-associe pour realiser du saut d'exons dans un gene codant une proteine a domaines dispensables |
| CN101432019A (zh) | 2004-10-05 | 2009-05-13 | 泰勒公司 | 用抗IgE抗体治疗和预防接受替代治疗的患者体内的超敏反应和/或过敏症 |
| WO2007001448A2 (en) | 2004-11-04 | 2007-01-04 | Massachusetts Institute Of Technology | Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals |
| CA2590675A1 (en) | 2004-12-15 | 2006-06-22 | Elan Pharma International Ltd. | Nanoparticulate tacrolimus formulations |
| EP1830824B1 (en) | 2004-12-31 | 2016-01-13 | Iceutica Pty Ltd. | Nanoparticle composition and methods for synthesis thereof |
| GB0504206D0 (en) | 2005-03-01 | 2005-04-06 | Glaxo Group Ltd | Combination therapy |
| BRPI0608573A2 (pt) | 2005-03-08 | 2017-07-25 | Lifecycle Pharma As | Composição farmacêutica, e, método para a preparação de uma composição farmacêutica. |
| MX2007011494A (es) * | 2005-03-17 | 2007-12-06 | Elan Pharma Int Ltd | Composiciones inyectables de compuestos inmunosupresores nanoparticulados. |
| US7884109B2 (en) | 2005-04-05 | 2011-02-08 | Wyeth Llc | Purine and imidazopyridine derivatives for immunosuppression |
| AU2006235538A1 (en) | 2005-04-12 | 2006-10-19 | Wisconsin Alumni Research Foundation | Micelle composition of polymer and passenger drug |
| WO2006122223A2 (en) | 2005-05-10 | 2006-11-16 | Emory University | Strategies for delivery of active agents using micelles and particles |
| CN102016814B (zh) | 2005-06-17 | 2013-10-23 | 北卡罗来纳大学查珀尔希尔分校 | 纳米粒子制备方法、系统及材料 |
| TW200711649A (en) * | 2005-06-17 | 2007-04-01 | Combinatorx Inc | Combination therapy for the treatment of immunoinflammatory disorders |
| JPWO2007024026A1 (ja) | 2005-08-25 | 2009-03-05 | 明石 満 | Ｔ細胞認識エピトープペプチドを固定化又は内包化した生分解性ナノ粒子 |
| CN1979166A (zh) * | 2005-11-30 | 2007-06-13 | 北京有色金属研究总院 | 一种制备免疫检测用纳米胶体金的工艺方法及其反应装置 |
| US20070202077A1 (en) | 2005-12-02 | 2007-08-30 | Brodsky Robert A | Use of High-Dose Oxazaphosphorine Drugs for Treating Immune Disorders |
| US20070128289A1 (en) * | 2005-12-07 | 2007-06-07 | Zhao Jonathon Z | Nano-and/or micro-particulate formulations for local injection-based treatment of vascular diseases |
| WO2007067683A2 (en) | 2005-12-08 | 2007-06-14 | University Of Louisville Research Foundation, Inc. | Methods and compositions for expanding t regulatory cells |
| WO2007070682A2 (en) | 2005-12-15 | 2007-06-21 | Massachusetts Institute Of Technology | System for screening particles |
| WO2007087341A2 (en) | 2006-01-25 | 2007-08-02 | The Board Of Trustees Of The University Of Illinois | Tolerogenic biodegradable artificial antigen presenting system |
| ES2551306T3 (es) | 2006-02-13 | 2015-11-17 | Oncolytics Biotech Inc. | Uso de inmunosupresión local de baja dosis para potenciar una terapia viral oncolítica |
| US8021689B2 (en) | 2006-02-21 | 2011-09-20 | Ecole Polytechnique Federale de Lausanne (“EPFL”) | Nanoparticles for immunotherapy |
| US8568487B2 (en) | 2006-02-27 | 2013-10-29 | Biomet Manufacturing, Llc | Patient-specific hip joint devices |
| BRPI0709340A2 (pt) | 2006-03-27 | 2013-04-16 | Globeimmune, Inc. | mutaÇço ras e composiÇÕes e mÉtodos de uso da mesma |
| CA2650607A1 (en) | 2006-04-28 | 2007-11-08 | Resolvyx Pharmaceuticals, Inc. | Compositions and methods for the treatment of cardiovascular disease |
| JP5630998B2 (ja) | 2006-05-15 | 2014-11-26 | マサチューセッツ インスティテュート オブ テクノロジー | 機能的粒子のためのポリマー |
| WO2007137117A2 (en) | 2006-05-17 | 2007-11-29 | Massachusetts Institute Of Technology | Aptamer-directed drug delivery |
| EP1880729A1 (en) | 2006-07-20 | 2008-01-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of soluble CD160 to suppress immunity |
| JP5570808B2 (ja) * | 2006-08-18 | 2014-08-13 | アルゴス・セラピューティクス・インコーポレーテッド | 併用療法におけるｃｄ８３の使用 |
| WO2008036374A2 (en) | 2006-09-21 | 2008-03-27 | Medistem Laboratories, Inc. | Allogeneic stem cell transplants in non-conditioned recipients |
| US8313777B2 (en) * | 2006-10-05 | 2012-11-20 | The Johns Hopkins University | Water-dispersible oral, parenteral, and topical formulations for poorly water soluble drugs using smart polymeric nanoparticles |
| CN101646418B (zh) | 2006-10-12 | 2013-07-17 | 昆士兰大学 | 调节免疫应答的组合物和方法 |
| AU2007306936B2 (en) | 2006-10-12 | 2014-02-06 | The University Of Queensland | Compositions and methods for modulating immune responses |
| US20100112077A1 (en) * | 2006-11-06 | 2010-05-06 | Abraxis Bioscience, Llc | Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer |
| WO2008064357A2 (en) | 2006-11-22 | 2008-05-29 | University Of Florida Research Foundation, Inc. | Nanoparticles for protection of cells from oxidative stress |
| WO2008069942A2 (en) | 2006-12-05 | 2008-06-12 | Biogen Idec Ma Inc. | Novel methods of enhancing delivery of a gene therapy vector using steroids |
| EP2118309B1 (en) | 2006-12-29 | 2015-01-28 | The Regents of the University of Colorado, a body corporate | Diagnostic and therapeutic target for autoimmune diseases and uses thereof |
| AU2008219020B2 (en) | 2007-02-21 | 2013-08-22 | Vaccinex, Inc. | Modulation of NKT cell activity with antigen-loaded CDId molecules |
| KR20080078204A (ko) | 2007-02-22 | 2008-08-27 | 크레아젠 주식회사 | 면역억제능이 증가된 간엽줄기세포-매개 자가유래수지상세포 |
| CN101678090B (zh) | 2007-03-07 | 2012-04-11 | 乌第有限合伙公司 | 用于预防和治疗自身免疫病的组合物和方法 |
| EP2131821B1 (en) | 2007-03-07 | 2018-05-09 | Abraxis BioScience, LLC | Nanoparticle comprising rapamycin and albumin as anticancer agent |
| CN101730526A (zh) * | 2007-03-07 | 2010-06-09 | 阿布拉科斯生物科学有限公司 | 作为抗癌剂的包含雷帕霉素和白蛋白的纳米颗粒 |
| JP2010523595A (ja) * | 2007-04-04 | 2010-07-15 | マサチューセッツ インスティテュート オブ テクノロジー | ポリ（アミノ酸）ターゲッティング部分 |
| ES2393814T3 (es) | 2007-04-04 | 2012-12-28 | Sigmoid Pharma Limited | Una composición farmacéutica oral |
| CA2683063A1 (en) | 2007-04-09 | 2008-10-16 | Chimeros, Inc. | Self-assembling nanoparticle drug delivery system |
| WO2008127532A1 (en) | 2007-04-12 | 2008-10-23 | Emory University | Novel strategies for delivery of active agents using micelles and particles |
| US20080311140A1 (en) | 2007-05-29 | 2008-12-18 | Baylor College Of Medicine | Antigen specific immunosuppression by dendritic cell therapy |
| WO2008150868A1 (en) | 2007-05-29 | 2008-12-11 | The Board Of Trustees Of The University Of Illinois | Methods for inducing therapeutic t cells for immune diseases |
| EP2468763B1 (en) | 2007-05-31 | 2014-06-18 | Academisch Ziekenhuis Leiden h.o.d.n. LUMC | HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines |
| BRPI0812205A2 (pt) | 2007-06-05 | 2014-11-25 | Novartis Ag | Indução de fenótipo tolerogênico em células dendríticas maduras |
| US20090004259A1 (en) | 2007-06-14 | 2009-01-01 | Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Conicet) | Methods of preparing a therapeutic formulation comprising galectin-induced tolerogenic dendritic cells |
| CN101809002B (zh) | 2007-07-09 | 2013-03-27 | 阿斯利康(瑞典)有限公司 | 用于与mtor激酶和/或pi3k相关的疾病中的吗啉代嘧啶衍生物 |
| GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
| NZ583362A (en) | 2007-08-15 | 2012-06-29 | Circassia Ltd | Peptide with reduced dimer formation |
| KR20100123674A (ko) | 2007-09-21 | 2010-11-24 | 싸이티뮨 사이언스, 인크. | 나노치료제 콜로이드성 금속 조성물 및 방법 |
| JP2011500569A (ja) * | 2007-10-12 | 2011-01-06 | マサチューセッツ インスティテュート オブ テクノロジー | ワクチンナノテクノロジー |
| WO2009062502A1 (en) | 2007-11-13 | 2009-05-22 | Dandrit Biotech A/S | Method for generating tolerogenic dendritic cells employing decreased temperature |
| US20090142318A1 (en) * | 2007-11-30 | 2009-06-04 | Therakos, Inc. | METHOD TO EXPAND nTREG CELLS USING p70 S6 KINASE ANTAGONIST |
| US8404658B2 (en) | 2007-12-31 | 2013-03-26 | Nanocor Therapeutics, Inc. | RNA interference for the treatment of heart failure |
| JP5474831B2 (ja) | 2008-02-08 | 2014-04-16 | テルモ株式会社 | 生理活性物質管腔内制御送達用薬剤送達装置およびその作成方法 |
| WO2009106999A2 (en) | 2008-02-28 | 2009-09-03 | Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts | Hollow nanoparticles and uses thereof |
| US9669057B2 (en) | 2008-04-25 | 2017-06-06 | Duke University | Regulatory B cells and their uses |
| AU2009246169B2 (en) | 2008-05-15 | 2015-01-22 | Dynavax Technologies Corporation | Long term disease modification using immunostimulatory oligonucleotides |
| WO2009145238A1 (ja) | 2008-05-27 | 2009-12-03 | 国立大学法人名古屋大学 | 免疫調節剤及びその利用 |
| US20090297621A1 (en) | 2008-06-03 | 2009-12-03 | Abbott Cardiovascular Systems Inc. | Microparticles For The Treatment Of Disease |
| EA020954B1 (ru) | 2008-06-16 | 2015-03-31 | Бинд Терапьютикс, Инк. | Загруженные лекарственным средством полимерные наночастицы, фармацевтическая композиция и способ лечения рака |
| WO2010005726A2 (en) | 2008-06-16 | 2010-01-14 | Bind Biosciences Inc. | Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same |
| US20110070154A1 (en) | 2008-08-13 | 2011-03-24 | Hyde Roderick A | Artificial cells |
| EP2331124A1 (en) | 2008-08-15 | 2011-06-15 | Circassia Limited | T-cell antigen peptide from allergen for stimulation of il-10 production |
| US8323696B2 (en) | 2008-08-29 | 2012-12-04 | Ecole Polytechnique Federale De Lausanne | Nanoparticles for immunotherapy |
| WO2010027471A2 (en) | 2008-09-04 | 2010-03-11 | The General Hospital Corporation | Hydrogels for vocal cord and soft tissue augmentation and repair |
| CN101676291B (zh) * | 2008-09-18 | 2012-05-09 | 上海海和药物研究开发有限公司 | 一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途 |
| US8889124B2 (en) | 2008-09-25 | 2014-11-18 | The Board Of Trustees Of The Leland Stanford Junior University | Tolerogenic populations of dendritic cells |
| WO2010037402A1 (en) | 2008-10-02 | 2010-04-08 | Dako Denmark A/S | Molecular vaccines for infectious disease |
| US8343498B2 (en) | 2008-10-12 | 2013-01-01 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
| US8591905B2 (en) | 2008-10-12 | 2013-11-26 | The Brigham And Women's Hospital, Inc. | Nicotine immunonanotherapeutics |
| US8343497B2 (en) | 2008-10-12 | 2013-01-01 | The Brigham And Women's Hospital, Inc. | Targeting of antigen presenting cells with immunonanotherapeutics |
| US8277812B2 (en) | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
| JP5552630B2 (ja) | 2008-10-24 | 2014-07-16 | 学校法人 聖マリアンナ医科大学 | Ｈｔｌｖ−ｉ関連脊髄症を治療または予防するための医薬、およびｈｔｌｖ−ｉ関連脊髄症の患者に対する抗体療法の効果を試験する方法 |
| US20120015899A1 (en) | 2008-10-25 | 2012-01-19 | Plant Bioscience, Limited | Modified plant virus particles and uses therefor |
| WO2010056143A1 (en) | 2008-11-13 | 2010-05-20 | Instituto De Medicina Molecular | The use of adjuvant to facilitate the induction of immune tolerance |
| JP2012512175A (ja) | 2008-12-15 | 2012-05-31 | バインド バイオサイエンシズ インコーポレイテッド | 治療薬を徐放するための長時間循環性ナノ粒子 |
| TW201039843A (en) | 2009-01-20 | 2010-11-16 | Myelin Repair Foundation Inc | Compositions and methods for induced tolerance |
| EP2218784A1 (en) | 2009-02-04 | 2010-08-18 | Universität Leipzig | Vector(s) containing an inducible gene encoding a CDK4/CD6 inhibitor useful for treating neurodegenerative disorders |
| HRP20150317T1 (hr) | 2009-02-05 | 2015-04-24 | Circassia Limited | Peptidi trave za cjepivo |
| KR20100099849A (ko) | 2009-03-04 | 2010-09-15 | 동국대학교 산학협력단 | 면역억제제와 트랜스글루타미나제 2의 억제제를 함유한 아토피 피부염 치료용 조성물 |
| WO2010114948A2 (en) | 2009-04-02 | 2010-10-07 | University Of Florida Research Foundation, Inc. | An inducible system for highly efficient production of recombinant adeno-associated virus (raav) vectors |
| GB0906159D0 (en) | 2009-04-09 | 2009-05-20 | Summit Corp Plc | Drug combination for the treatment of proteostatic diseases |
| JP2012524780A (ja) | 2009-04-21 | 2012-10-18 | セレクタ バイオサイエンシーズ インコーポレーテッド | Ｔｈ１バイアス応答をもたらす免疫ナノ治療薬（Ｉｍｍｕｎｏｎａｎｏｔｈｅｒａｐｅｕｔｉｃｓ） |
| WO2010123501A1 (en) | 2009-04-22 | 2010-10-28 | Massachusetts Institute Of Technology | Innate immune suppression enables repeated delivery of long rna molecules |
| CA2760096C (en) | 2009-04-27 | 2018-10-30 | Immuron Limited | Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder. |
| BRPI1012036A2 (pt) | 2009-05-27 | 2017-10-10 | Selecta Biosciences Inc | nanocarreadores que possuem componentes com diferentes taxas de liberação |
| US9377454B2 (en) | 2009-06-25 | 2016-06-28 | Crealta Pharmaceuticals Llc | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy |
| ES2641892T3 (es) | 2009-08-26 | 2017-11-14 | Selecta Biosciences, Inc. | Composiciones que inducen la ayuda de las células T |
| AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| EP2305277A1 (en) | 2009-09-18 | 2011-04-06 | Forskarpatent I Syd AB | Use of tolerogenic dendritic cells in treatment and prevention of atherosclerosis |
| CN101703781A (zh) | 2009-10-28 | 2010-05-12 | 陕西北美基因股份有限公司 | 一种免疫抑制剂的磁性载药方法 |
| KR101267813B1 (ko) * | 2009-12-30 | 2013-06-04 | 주식회사 삼양바이오팜 | 향상된 수용해도를 갖는 라파마이신 함유 고분자나노입자 주사제형 조성물 및 그 제조방법, 및 방사선 요법과 병용하기 위한 항암 조성물 |
| WO2011085231A2 (en) | 2010-01-08 | 2011-07-14 | Selecta Biosciences, Inc. | Synthetic virus-like particles conjugated to human papillomavirus capsid peptides for use as vaccines |
| US9228171B2 (en) | 2010-02-05 | 2016-01-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Regulatory B cells (tBREGS) and their use |
| EP2542670A2 (en) | 2010-03-05 | 2013-01-09 | President and Fellows of Harvard College | Induced dendritic cell compositions and uses thereof |
| US20110262491A1 (en) | 2010-04-12 | 2011-10-27 | Selecta Biosciences, Inc. | Emulsions and methods of making nanocarriers |
| US20110272836A1 (en) | 2010-04-12 | 2011-11-10 | Selecta Biosciences, Inc. | Eccentric vessels |
| US8927514B2 (en) | 2010-04-30 | 2015-01-06 | City Of Hope | Recombinant adeno-associated vectors for targeted treatment |
| BR112012028557A2 (pt) | 2010-05-07 | 2019-09-24 | Xoma Technology Ltd. | uso de um anticorpo anti-il-1b ou de fragmentos de ligação do mesmo. |
| CA2798739A1 (en) | 2010-05-26 | 2011-12-01 | Selecta Biosciences, Inc. | Nanocarrier compositions with uncoupled adjuvant |
| JP6031437B2 (ja) * | 2010-06-07 | 2016-11-24 | アブラクシス バイオサイエンス， エルエルシー | 増殖性疾患を処置するための組み合わせ療法 |
| EP2600878A4 (en) | 2010-08-04 | 2014-06-11 | Univ Duke | REGULATORY B-CELLS AND ITS USES |
| EP2603520A4 (en) | 2010-08-10 | 2014-02-19 | Ecole Polytech | ERYTHROCYTE BINDING THERAPEUTICS |
| WO2012024621A2 (en) | 2010-08-20 | 2012-02-23 | Selecta Biosciences, Inc. | Synthetic nanocarrier vaccines comprising peptides obtained or derived from human influenza a virus hemagglutinin |
| JP2013538211A (ja) * | 2010-08-23 | 2013-10-10 | セレクタ バイオサイエンシーズ インコーポレーテッド | 抗原に対する免疫反応を誘発する標的マルチエピトープ剤形 |
| US9636309B2 (en) | 2010-09-09 | 2017-05-02 | Micell Technologies, Inc. | Macrolide dosage forms |
| US10016371B2 (en) | 2010-10-22 | 2018-07-10 | University Of Florida Research Foundation | Antigen-specific, tolerance-inducing microparticles and uses thereof |
| EA201390660A1 (ru) | 2010-11-05 | 2013-11-29 | Селекта Байосайенсиз, Инк. | Модифицированные никотиновые соединения и связанные способы |
| US20120171229A1 (en) | 2010-12-30 | 2012-07-05 | Selecta Biosciences, Inc. | Synthetic nanocarriers with reactive groups that release biologically active agents |
| EP2672977A1 (en) | 2011-02-08 | 2013-12-18 | The Charlotte-Mecklenburg Hospital Authority d/b/a Carolina Healthcare System | Antisense oligonucleotides |
| EP2675484B1 (en) | 2011-02-14 | 2018-05-30 | The Children's Hospital of Philadelphia | Improved aav8 vector with enhanced functional activity and methods of use thereof |
| US8654487B2 (en) | 2011-03-11 | 2014-02-18 | Siemens Industry, Inc. | Methods, systems, and apparatus and for detecting parallel electrical arc faults |
| MX366228B (es) | 2011-03-25 | 2019-07-03 | Selecta Biosciences Inc | Nanoportadores sinteticos de liberacion mediada por osmosis. |
| AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| US20140155469A1 (en) | 2011-04-19 | 2014-06-05 | The Research Foundation Of State University Of New York | Adeno-associated-virus rep sequences, vectors and viruses |
| WO2012145572A1 (en) | 2011-04-20 | 2012-10-26 | The Trustees Of The University Of Pennsylvania | Regimens and compositions for aav-mediated passive immunization of airborne pathogens |
| MX374963B (es) | 2011-04-29 | 2025-03-06 | Selecta Biosciences Inc | Nanoportadores sintéticos tolerogénicos para reducir las respuestas de anticuerpos. |
| SG194802A1 (en) * | 2011-05-16 | 2013-12-30 | Genzyme Corp | Induction of immune tolerance by using methotrexate |
| KR20140050698A (ko) | 2011-07-29 | 2014-04-29 | 셀렉타 바이오사이언시즈, 인크. | 체액성 및 세포독성 t 림프구(ctl) 면역 반응을 발생시키는 합성 나노운반체 |
| WO2013036301A1 (en) | 2011-09-06 | 2013-03-14 | Selecta Biosciences, Inc. | Induced tolerogenic dendritic cells for inducing regulatory b cells |
| WO2013036914A1 (en) | 2011-09-08 | 2013-03-14 | University Of Florida Research Foundation, Inc. | Materials and methods for modulating immune responses |
| US8865487B2 (en) | 2011-09-20 | 2014-10-21 | General Electric Company | Large area hermetic encapsulation of an optoelectronic device using vacuum lamination |
| DE19216461T1 (de) | 2011-10-03 | 2021-10-07 | Modernatx, Inc. | Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon |
| WO2013058812A1 (en) | 2011-10-19 | 2013-04-25 | President And Fellows Of Harvard College | Targeted delivery to pancreatic islet endothelial cells |
| EP2591801A1 (en) | 2011-11-14 | 2013-05-15 | Universitätsklinikum Hamburg-Eppendorf | Nanoparticle compositions for generation of regulatory T cells and treatment of autoimmune diseases and other chronic inflammatory conditions |
| HK1202434A1 (en) | 2011-11-22 | 2015-10-02 | The Children's Hospital Of Philadelphia | Virus vectors for highly efficient transgene delivery |
| MX367100B (es) | 2012-02-17 | 2019-08-05 | The Children´S Hospital Of Philadelphia | Composiciones del vector aav y metodos para su transferencia genetica a celulas, organos y tejidos. |
| NZ701693A (en) | 2012-04-18 | 2017-02-24 | The Children’S Hospital Of Philadelphia | Composition and methods for highly efficient gene transfer using aav capsid variants |
| CA2871786C (en) | 2012-04-24 | 2021-11-16 | Ohio State Innovation Foundation | Compositions and methods for treating and preventing porcine reproductive and respiratory syndrome |
| EP2895146A1 (en) | 2012-09-17 | 2015-07-22 | BIND Therapeutics, Inc. | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same |
| CN102871966B (zh) | 2012-10-19 | 2013-11-20 | 东南大学 | 用于改善雷帕霉素生物利用度的纳米载药颗粒及其制备方法 |
| EP2968499A4 (en) | 2013-03-15 | 2016-11-30 | Haplomics Inc | COMPOSITIONS AND METHODS FOR THE IMMUNO-TOLERANCE INDUCTION FOR FACTOR VIII SPATIAL THERAPIES IN PERSONS WITH HEMOPHILIA A |
| US9944918B2 (en) | 2013-03-15 | 2018-04-17 | The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services | Synthetic methylmalonyl-CoA mutase transgene for the treatment of MUT class methylmalonic acidemia (MMA) |
| WO2014168953A1 (en) | 2013-04-08 | 2014-10-16 | University Of Iowa Research Foundation | Chimeric adeno-associated virus/ bocavirus parvovirus vector |
| TWI679019B (zh) | 2013-04-29 | 2019-12-11 | 法商賽諾菲公司 | 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物 |
| BR122020023215B1 (pt) | 2013-05-03 | 2022-11-22 | Selecta Biosciences, Inc | Composição e kit de nanocarreadores sintéticos tolerogênicos para reduzir ou prevenir anafilaxia em resposta a um antígeno não alergênico |
| AU2014262164B2 (en) | 2013-05-03 | 2020-02-27 | Selecta Biosciences, Inc. | Dosing combinations for reducing undesired humoral immune responses |
| BR112015030237A2 (pt) | 2013-06-04 | 2017-10-03 | Selecta Biosciences Inc | Imunoterapêutico antígeno-específico, composição, método de fabricação e seu uso |
| WO2015051199A2 (en) | 2013-10-06 | 2015-04-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modified pseudomonas exotoxin a |
| US9276815B2 (en) * | 2013-12-27 | 2016-03-01 | Dell Products L.P. | N-node virtual link trunking (VLT) systems management plane |
| EP2916319A1 (en) | 2014-03-07 | 2015-09-09 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Concept for encoding of information |
| SMT202000531T1 (it) | 2014-03-09 | 2020-11-10 | Univ Pennsylvania | Composizioni utili in trattamento di deficit di ornitina transcarbamilasi(otc) |
| GB201407322D0 (en) | 2014-04-25 | 2014-06-11 | Ospedale San Raffaele | Gene therapy |
| US20150358333A1 (en) * | 2014-06-04 | 2015-12-10 | Grandios Technologies, Llc | Geo-location and biometric presence security |
| US20150359865A1 (en) | 2014-06-17 | 2015-12-17 | Selecta Biosciences, Inc. | Tolerogenic synthetic nanocarriers for t-cell-mediated autoimmune disease |
| US20160220501A1 (en) | 2015-02-03 | 2016-08-04 | Selecta Biosciences, Inc. | Tolerogenic synthetic nanocarriers to reduce immune responses to therapeutic proteins |
| WO2015200728A1 (en) | 2014-06-25 | 2015-12-30 | Selecta Biosciences, Inc. | Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors |
| JP7242180B2 (ja) | 2014-09-07 | 2023-03-20 | セレクタ バイオサイエンシーズ インコーポレーテッド | 抗ウイルス導入ベクター免疫応答を減弱化するための方法および組成物 |
| EP3204503A1 (en) | 2014-10-06 | 2017-08-16 | Arthrogen BV | Aav-based gene therapy |
| KR102601922B1 (ko) | 2014-11-05 | 2023-11-15 | 셀렉타 바이오사이언시즈, 인크. | 안정한 과-포화 상태로 라파마이신을 포함하는 합성 나노담체와 관련된 방법 및 조성물 |
| KR20180030030A (ko) | 2015-07-15 | 2018-03-21 | 교와 핫꼬 기린 가부시키가이샤 | 인간 crth2에 특이적으로 결합하는 항체 |
| WO2017139212A1 (en) | 2016-02-08 | 2017-08-17 | Cyta Therapeutics, Inc. | Particle delivery of rapamycin to the liver |
| CN108697815A (zh) | 2016-02-10 | 2018-10-23 | 辉瑞公司 | 具有egfr配体的治疗性纳米颗粒及其制备和使用方法 |
| KR20180120753A (ko) | 2016-03-11 | 2018-11-06 | 셀렉타 바이오사이언시즈, 인크. | Peg화 우리카제의 제제 및 용량 |
| GB201608323D0 (en) | 2016-05-12 | 2016-06-29 | Ucb Biopharma Sprl | Pharmaceutical compositions |
| US10545815B2 (en) | 2016-08-03 | 2020-01-28 | Futurewei Technologies, Inc. | System and method for data redistribution in a database |
| WO2018039465A1 (en) | 2016-08-25 | 2018-03-01 | Selecta Biosciences, Inc. | Polyester polymer matrices for the delivery of allergens |
| CA3038089A1 (en) | 2016-09-27 | 2018-04-05 | Selecta Biosciences, Inc. | Recombinant immunotoxins for use in the treatment of cancer |
| US11583504B2 (en) | 2016-11-08 | 2023-02-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| WO2018093868A1 (en) | 2016-11-16 | 2018-05-24 | University Of Florida Research Foundation, Inc. | Immunoglobulin proteases, compositions, and uses thereof |
| WO2018127382A1 (en) | 2017-01-03 | 2018-07-12 | Ethris Gmbh | Ornithine transcarbamylase coding polyribonucleotides and formulations thereof |
| MX2019008143A (es) | 2017-01-07 | 2020-01-13 | Selecta Biosciences Inc | Dosificación sistemática de inmunosupresores acoplados a nanoportadores sintéticos. |
| ES3036482T3 (en) | 2017-03-11 | 2025-09-19 | Cartesian Therapeutics Inc | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
| BR112020007157A2 (pt) | 2017-10-13 | 2020-09-24 | Selecta Biosciences, Inc. | métodos e composições para a atenuação de respostas de igm antivetor de transferência viral |
| WO2019162951A1 (en) | 2018-02-26 | 2019-08-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Drug delivery systems |
| US11517628B2 (en) | 2018-05-09 | 2022-12-06 | Yale University | Particles for spatiotemporal release of agents |
| CN112654370A (zh) | 2018-07-16 | 2021-04-13 | 西莱克塔生物科技公司 | Mma构建体和载体的方法和组合物 |
| WO2020018583A1 (en) | 2018-07-16 | 2020-01-23 | Selecta Biosciences, Inc. | Methods and compositions of otc constructs and vectors |
| EP3962537A1 (en) | 2019-04-28 | 2022-03-09 | Selecta Biosciences, Inc. | Methods for treatment of subjects with preexisting immunity to viral transfer vectors |
| CN114206396A (zh) | 2019-05-28 | 2022-03-18 | 西莱克塔生物科技公司 | 用于减弱抗病毒转移载体免疫应答的方法和组合物 |
| AU2020287627A1 (en) | 2019-06-04 | 2021-11-18 | Selecta Biosciences, Inc. | Formulations and doses of PEGylated uricase |
| EP4048269A1 (en) | 2019-10-21 | 2022-08-31 | Selecta Biosciences, Inc. | Methods and compositions for treating liver diseases and disorders |
| CN118384281A (zh) | 2019-11-08 | 2024-07-26 | 西莱克塔生物科技公司 | 聚乙二醇化尿酸酶的制剂和剂量 |
| AU2021225955A1 (en) | 2020-02-26 | 2022-09-22 | Selecta Biosciences, Inc. | Methods and compositions using synthetic nanocarriers comprising immunosuppressant |
| MX2022011248A (es) | 2020-03-11 | 2022-12-15 | Selecta Biosciences Inc | Metodos y composiciones relacionados con nanoportadores sinteticos. |
| CN120078887A (zh) | 2020-09-21 | 2025-06-03 | 上海宝济药业股份有限公司 | 一种药物组合及其应用 |
| MX2023005224A (es) | 2020-11-04 | 2023-07-18 | Selecta Biosciences Inc | Composiciones para reducir las respuestas inmunes contra inmunoglobulina proteasas. |
| WO2022150335A1 (en) | 2021-01-05 | 2022-07-14 | Selecta Biosciences, Inc. | Viral vector dosing protocols |
| KR20230167405A (ko) | 2021-04-09 | 2023-12-08 | 셀렉타 바이오사이언시즈, 인크. | 면역 관용을 증진시키기 위해 고친화도 il-2 수용체 효능제와 조합된 면역억제제를 포함하는 합성 나노담체 |
| EP4079848A1 (en) | 2021-04-22 | 2022-10-26 | Genovis Ab | Immunoglobulin cleaving enzyme |
| US20230141563A1 (en) | 2021-10-12 | 2023-05-11 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector igm responses |
| WO2023064350A1 (en) | 2021-10-12 | 2023-04-20 | Selecta Biosciences, Inc. | Viral vector dosing protocols |
| WO2023172624A1 (en) | 2022-03-09 | 2023-09-14 | Selecta Biosciences, Inc. | Immunosuppressants in combination with anti-igm agents and related dosing |
| CN120813689A (zh) | 2022-08-11 | 2025-10-17 | 笛卡尔疗法股份有限公司 | 与免疫球蛋白蛋白酶及其融合体相关的组合物和方法 |
-
2014
- 2014-05-02 BR BR122020023215-3A patent/BR122020023215B1/pt active IP Right Grant
- 2014-05-02 CN CN201480034670.3A patent/CN105338968A/zh active Pending
- 2014-05-02 EA EA201592107A patent/EA201592107A1/ru unknown
- 2014-05-02 WO PCT/US2014/036687 patent/WO2014179762A1/en not_active Ceased
- 2014-05-02 CN CN201480031937.3A patent/CN105307641A/zh active Pending
- 2014-05-02 AU AU2014262165A patent/AU2014262165B2/en active Active
- 2014-05-02 CA CA2910417A patent/CA2910417C/en active Active
- 2014-05-02 CN CN202410981673.3A patent/CN118987263A/zh active Pending
- 2014-05-02 AU AU2014262166A patent/AU2014262166B2/en active Active
- 2014-05-02 EP EP14791089.7A patent/EP2991628A4/en active Pending
- 2014-05-02 CN CN201910874452.5A patent/CN110639024A/zh active Pending
- 2014-05-02 CN CN201480032224.9A patent/CN105263478A/zh active Pending
- 2014-05-02 US US14/269,047 patent/US10434088B2/en active Active
- 2014-05-02 EP EP14791147.3A patent/EP2991685A4/en not_active Withdrawn
- 2014-05-02 KR KR1020247024661A patent/KR20240119155A/ko not_active Ceased
- 2014-05-02 CN CN201911069459.6A patent/CN110841066A/zh active Pending
- 2014-05-02 EP EP14792080.5A patent/EP2991631A4/en active Pending
- 2014-05-02 KR KR1020247024665A patent/KR20240119157A/ko active Pending
- 2014-05-02 KR KR1020227004756A patent/KR20220025906A/ko not_active Ceased
- 2014-05-02 KR KR1020227004759A patent/KR20220025908A/ko not_active Ceased
- 2014-05-02 MX MX2015015230A patent/MX386917B/es unknown
- 2014-05-02 CA CA2910575A patent/CA2910575C/en active Active
- 2014-05-02 KR KR1020157034104A patent/KR20160003830A/ko not_active Ceased
- 2014-05-02 CN CN202010594054.0A patent/CN111686255A/zh active Pending
- 2014-05-02 US US14/269,042 patent/US20140335186A1/en active Pending
- 2014-05-02 EA EA201592104A patent/EA201592104A3/ru unknown
- 2014-05-02 JP JP2016512092A patent/JP6760838B2/ja active Active
- 2014-05-02 BR BR112015027281-9A patent/BR112015027281B1/pt active IP Right Grant
- 2014-05-02 CN CN201480032251.6A patent/CN105283175A/zh active Pending
- 2014-05-02 MX MX2015015221A patent/MX394497B/es unknown
- 2014-05-02 CA CA2910584A patent/CA2910584A1/en active Pending
- 2014-05-02 EA EA201592102A patent/EA201592102A1/ru unknown
- 2014-05-02 MX MX2015015229A patent/MX2015015229A/es unknown
- 2014-05-02 BR BR112015027297-5A patent/BR112015027297B1/pt active IP Right Grant
- 2014-05-02 CN CN201480037123.0A patent/CN105339012A/zh active Pending
- 2014-05-02 JP JP2016512094A patent/JP6580558B2/ja active Active
- 2014-05-02 CN CN201480037076.XA patent/CN105338979A/zh active Pending
- 2014-05-02 KR KR1020157034133A patent/KR20160003217A/ko not_active Ceased
- 2014-05-02 JP JP2016512093A patent/JP6818549B2/ja active Active
- 2014-05-02 IL IL284732A patent/IL284732B2/en unknown
- 2014-05-02 KR KR1020157034120A patent/KR20160003214A/ko not_active Ceased
- 2014-05-02 KR KR1020227004760A patent/KR20220025909A/ko not_active Ceased
- 2014-05-02 JP JP2016512086A patent/JP2016517889A/ja active Pending
- 2014-05-02 EP EP20167362.1A patent/EP3763359A1/en not_active Withdrawn
- 2014-05-02 JP JP2016512091A patent/JP7028556B2/ja active Active
- 2014-05-02 MX MX2021005697A patent/MX2021005697A/es unknown
- 2014-05-02 US US14/269,054 patent/US10357482B2/en active Active
- 2014-05-02 MX MX2015015223A patent/MX380164B/es unknown
- 2014-05-02 WO PCT/US2014/036697 patent/WO2014179770A1/en not_active Ceased
- 2014-05-02 IL IL292190A patent/IL292190A/en unknown
- 2014-05-02 JP JP2016512090A patent/JP2016520051A/ja active Pending
- 2014-05-02 WO PCT/US2014/036699 patent/WO2014179772A2/en not_active Ceased
- 2014-05-02 US US14/269,056 patent/US10357483B2/en active Active
- 2014-05-02 EP EP14791567.2A patent/EP2991630A4/en active Pending
- 2014-05-02 BR BR112015027279A patent/BR112015027279A8/pt not_active Application Discontinuation
- 2014-05-02 KR KR1020227004761A patent/KR20220025910A/ko not_active Ceased
- 2014-05-02 CN CN201910552107.XA patent/CN110251676A/zh active Pending
- 2014-05-02 KR KR1020157034143A patent/KR20160003219A/ko not_active Ceased
- 2014-05-02 KR KR1020227004763A patent/KR20220025911A/ko not_active Ceased
- 2014-05-02 HU HUE14791496A patent/HUE052599T2/hu unknown
- 2014-05-02 CN CN201911306104.4A patent/CN111068061A/zh active Pending
- 2014-05-02 AU AU2014262163A patent/AU2014262163A1/en not_active Abandoned
- 2014-05-02 ES ES14791496T patent/ES2842206T3/es active Active
- 2014-05-02 EP EP14791119.2A patent/EP2991629A4/en active Pending
- 2014-05-02 KR KR1020247024763A patent/KR20240119160A/ko not_active Ceased
- 2014-05-02 KR KR1020247024664A patent/KR20240119156A/ko not_active Ceased
- 2014-05-02 WO PCT/US2014/036696 patent/WO2014179769A2/en not_active Ceased
- 2014-05-02 CN CN202410347642.2A patent/CN118370823A/zh active Pending
- 2014-05-02 CN CN201910552053.7A patent/CN110251675A/zh active Pending
- 2014-05-02 EP EP14791496.4A patent/EP2991646B1/en active Active
- 2014-05-02 KR KR1020227004758A patent/KR20220025907A/ko not_active Ceased
- 2014-05-02 KR KR1020247024766A patent/KR20240119161A/ko active Pending
- 2014-05-02 MX MX2015015225A patent/MX382604B/es unknown
- 2014-05-02 IL IL284924A patent/IL284924B2/en unknown
- 2014-05-02 CN CN202010594335.6A patent/CN111760025A/zh active Pending
- 2014-05-02 CN CN201911069542.3A patent/CN110841067A/zh active Pending
- 2014-05-02 EA EA201592103A patent/EA201592103A3/ru unknown
- 2014-05-02 EA EA201592105A patent/EA201592105A1/ru unknown
- 2014-05-02 KR KR1020157034102A patent/KR20160003212A/ko not_active Ceased
- 2014-05-02 DK DK14791496.4T patent/DK2991646T3/da active
- 2014-05-02 CN CN201910874364.5A patent/CN110694077A/zh active Pending
- 2014-05-02 CA CA2910578A patent/CA2910578C/en active Active
- 2014-05-02 BR BR112015027291A patent/BR112015027291A8/pt not_active Application Discontinuation
- 2014-05-02 US US14/269,058 patent/US10335395B2/en active Active
- 2014-05-02 CN CN201911307714.6A patent/CN111053908A/zh active Pending
- 2014-05-02 EA EA201592106A patent/EA201592106A3/ru unknown
- 2014-05-02 BR BR112015027288-6A patent/BR112015027288B1/pt active IP Right Grant
- 2014-05-02 MX MX2015015231A patent/MX2015015231A/es unknown
- 2014-05-02 CA CA2910583A patent/CA2910583C/en active Active
- 2014-05-02 KR KR1020247024767A patent/KR20240116963A/ko active Pending
- 2014-05-02 AU AU2014262155A patent/AU2014262155A1/en not_active Abandoned
- 2014-05-02 WO PCT/US2014/036700 patent/WO2014179773A2/en not_active Ceased
- 2014-05-02 US US14/269,048 patent/US10668053B2/en active Active
- 2014-05-02 KR KR1020157034121A patent/KR20160003215A/ko not_active Ceased
- 2014-05-02 AU AU2014262162A patent/AU2014262162B2/en active Active
-
2015
- 2015-10-22 IL IL24221615A patent/IL242216B/en active IP Right Grant
- 2015-10-26 IL IL242273A patent/IL242273B/en active IP Right Grant
- 2015-10-26 IL IL242272A patent/IL242272B/en active IP Right Grant
- 2015-10-26 IL IL24227015A patent/IL242270B/en active IP Right Grant
- 2015-10-26 IL IL242271A patent/IL242271B/en active IP Right Grant
- 2015-10-30 MX MX2021001878A patent/MX2021001878A/es unknown
- 2015-10-30 MX MX2021001879A patent/MX2021001879A/es unknown
- 2015-10-30 MX MX2021012348A patent/MX2021012348A/es unknown
- 2015-10-30 MX MX2022009538A patent/MX2022009538A/es unknown
- 2015-10-30 MX MX2021001982A patent/MX2021001982A/es unknown
-
2018
- 2018-12-10 JP JP2018231206A patent/JP6983144B2/ja active Active
-
2019
- 2019-01-15 JP JP2019004287A patent/JP7134885B2/ja active Active
- 2019-05-13 US US16/410,876 patent/US20200069659A1/en not_active Abandoned
- 2019-06-06 US US16/433,622 patent/US20200069660A1/en not_active Abandoned
- 2019-06-11 US US16/438,147 patent/US11298342B2/en active Active
- 2019-08-26 US US16/550,725 patent/US20200113874A1/en not_active Abandoned
- 2019-08-28 JP JP2019155456A patent/JP2020015741A/ja active Pending
- 2019-10-15 AU AU2019250117A patent/AU2019250117B2/en active Active
- 2019-10-24 IL IL270135A patent/IL270135B/en unknown
- 2019-10-24 IL IL270133A patent/IL270133B/en unknown
- 2019-10-28 JP JP2019195263A patent/JP7427419B2/ja active Active
- 2019-12-02 JP JP2019217946A patent/JP2020073488A/ja active Pending
-
2020
- 2020-01-04 AU AU2020200065A patent/AU2020200065B2/en active Active
- 2020-01-24 AU AU2020200565A patent/AU2020200565A1/en not_active Abandoned
- 2020-02-05 AU AU2020200824A patent/AU2020200824A1/en not_active Abandoned
- 2020-04-24 US US16/858,349 patent/US12508249B2/en active Active
- 2020-05-21 IL IL274852A patent/IL274852B/en unknown
- 2020-05-21 AU AU2020203308A patent/AU2020203308A1/en not_active Abandoned
- 2020-07-21 IL IL276205A patent/IL276205B/en active IP Right Grant
-
2021
- 2021-01-04 JP JP2021000191A patent/JP2021073198A/ja active Pending
- 2021-03-24 US US17/211,459 patent/US20220071968A1/en not_active Abandoned
- 2021-04-04 IL IL282045A patent/IL282045B/en unknown
- 2021-09-30 JP JP2021162235A patent/JP7489362B2/ja active Active
- 2021-11-29 JP JP2021193530A patent/JP2022043071A/ja active Pending
-
2022
- 2022-01-12 AU AU2022200157A patent/AU2022200157A1/en not_active Abandoned
- 2022-03-09 US US17/690,437 patent/US12472167B2/en active Active
- 2022-03-09 AU AU2022201641A patent/AU2022201641B2/en active Active
- 2022-03-15 IL IL291394A patent/IL291394A/en unknown
- 2022-05-06 JP JP2022076702A patent/JP2022122871A/ja active Pending
- 2022-05-06 JP JP2022076787A patent/JP7440833B2/ja active Active
- 2022-05-11 AU AU2022203142A patent/AU2022203142B2/en active Active
- 2022-05-25 AU AU2022203540A patent/AU2022203540A1/en not_active Abandoned
- 2022-12-09 JP JP2022197386A patent/JP2023039981A/ja active Pending
-
2023
- 2023-05-11 AU AU2023202955A patent/AU2023202955A1/en not_active Abandoned
- 2023-12-01 US US18/527,060 patent/US20240350462A1/en active Pending
-
2024
- 2024-05-13 JP JP2024077998A patent/JP2024116128A/ja active Pending
- 2024-06-28 US US18/757,781 patent/US20250177360A1/en active Pending
- 2024-08-21 AU AU2024213104A patent/AU2024213104A1/en not_active Abandoned
- 2024-09-13 JP JP2024159048A patent/JP2025003994A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022115998A5 (https=) | ||
| JP2022025069A5 (https=) | ||
| JP2022043071A5 (https=) | ||
| JP2019089784A5 (https=) | ||
| JP2020015741A5 (https=) | ||
| JP2020045343A5 (https=) | ||
| JP2019069964A5 (https=) | ||
| JP2016517891A5 (https=) | ||
| JP2016520051A5 (https=) | ||
| JP2016517890A5 (https=) | ||
| JP2016517889A5 (https=) | ||
| JP2017114904A5 (https=) | ||
| JP2016518392A5 (https=) | ||
| JP2021183613A5 (https=) | ||
| JP2014513102A5 (https=) | ||
| RU2338752C2 (ru) | Производные фактора vii свертывания крови | |
| JP2022530615A (ja) | 嚥下可能な薬物送達デバイスを使用する腸管の組織への送達のための凝固因子調製物 | |
| JP2010006839A (ja) | 組織因子経路インヒビター（ｔｆｐｉ）の低量投与による敗血症の処置 | |
| KR102137290B1 (ko) | 최적화된 피하 치료약 | |
| US20100286061A1 (en) | Plasmin-inhibitory therapies | |
| CN105848668A (zh) | 治疗或预防与出血或低凝血相关联的病状的疗法 | |
| Powell | Longer‐acting clotting factor concentrates for hemophilia | |
| JP2023531679A (ja) | 血友病を処置するための方法および組成物 | |
| JP2020502133A (ja) | 肺の繊維化を予防及び治療するための方法 | |
| US11007253B2 (en) | Method for preventing or treating radiation and chemical damage |